- Home
- CMMB vs NCNA Comparison
CMMB vs NCNA Comparison
Compare CMMB & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | NCNA |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 13.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CMMB | NCNA |
|---|---|---|
| Price | $1.88 | $3.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $26.50 | N/A |
| AVG Volume (30 Days) | ★ 107.0K | 59.2K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $2.78 |
| 52 Week High | $9.84 | $273.92 |
Technical Indicators
Market Signals| Indicator | CMMB | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 48.29 |
| Support Level | $1.60 | $3.16 |
| Resistance Level | $1.96 | $3.78 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 43.87 | 75.81 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.